What “Polyendocrine Metabolic Ovarian” Actually Means

Three words describing what the condition formerly called PCOS actually is. What each one means biologically, and what each one means for the way the condition is treated.

By Dr Gautam V. DaftaryDirector, Aksigen IVF

Last reviewed June 20266-minute read1,375 words

The new name for what used to be called PCOS — polyendocrine metabolic ovarian syndrome — is a three-word description of what the condition actually is. Each word does specific work. Understanding what each one means gives you a working clinical framework for the condition itself, not just its label.

The three words function as a hierarchy. Polyendocrine names the multi-system biological interaction that produces the condition.Metabolic names the dimension that matters most to long-term health.Ovarian names the feature that brings most women to a specialist. Read in that order, the name describes how to think about PMOS clinically — what is fundamental, what is consequential, and what is acute.

Polyendocrine

The endocrine system is the network of glands and organs that produce hormones — chemical signals that travel through the bloodstream to regulate processes elsewhere in the body. The thyroid is part of the endocrine system; so are the adrenal glands above the kidneys, the pancreas, the ovaries, the pituitary gland at the base of the brain, and the hypothalamus that sits above it.

The prefix poly simply means multiple. A polyendocrine condition is one that involves multiple endocrine systems simultaneously.

In PMOS, four endocrine systems interact to produce the condition¹.

The first is the hypothalamic-pituitary system in the brain. The hypothalamus releases gonadotropin-releasing hormone (GnRH) in pulses; in PMOS, these pulses come more rapidly than normal, which biases the pituitary toward producing more luteinising hormone (LH) than follicle-stimulating hormone (FSH).

The second is the ovary. The altered LH-to-FSH ratio drives the ovary to produce more androgens — testosterone and androstenedione — than it normally would. This is the source of the clinical signs of hyperandrogenism: acne, hirsutism, hair thinning.

The third is the pancreas. In a majority of women with PMOS, the body's cells require more insulin to do their normal work — a state called insulin resistance. The pancreas compensates by producing more insulin. Elevated insulin then loops back to the ovaries and directly stimulates further androgen production, and simultaneously lowers sex hormone-binding globulin in the blood, which increases the biologically active fraction of the androgens that are already elevated.

The fourth is the adrenal gland. The adrenals also produce androgens — particularly DHEAS — and in many women with PMOS, the adrenal contribution adds meaningfully to the overall androgen load.

These four systems do not operate independently. They are tied together in a self-reinforcing loop, and that interconnection is exactly what the word polyendocrine names. Treating PMOS effectively means addressing the loop, not just one part of it.

Metabolic

Metabolism is the set of biological processes through which the body converts food into energy and the building blocks of tissue, and through which it stores, mobilises, and disposes of that energy across the day. Metabolic health is how well those processes work — how the body handles glucose, how it stores and releases fat, how it manages cholesterol and other lipids, how stable the body's energy state remains across hours and years.

The decision to put metabolic as the second word in PMOS reflects a shift in how the medical community understands the condition. For most of its history under the PCOS name, the metabolic dimensions of the condition were treated as complications — things that might happen later if the underlying reproductive disorder were not managed. The renaming reverses that hierarchy. Metabolic disturbance is now understood as central to PMOS, not downstream of it².

The metabolic features that define PMOS include insulin resistance, central adiposity (weight that accumulates around the abdomen rather than evenly across the body), dyslipidaemia (an unfavourable lipid pattern in the blood), and elevated cardiovascular risk markers. Not every woman with PMOS has all of these, but most have several, and the pattern often emerges before the diagnostic conversation has identified the underlying condition.

The long-term consequences of these metabolic features are substantial. The most-cited meta-analysis on long-term risk in PMOS quantified elevated odds of type 2 diabetes, hypertension, dyslipidaemia, non-fatal stroke, and metabolic syndrome across the lifespan³. The 2024 update from the same research group confirmed elevated clinical cardiovascular disease risk specifically⁴.

The clinical implication of the metabolic framing is that treatment must address the metabolic dimension regardless of whether the woman is currently trying to conceive. A 25-year-old PMOS patient who is not currently planning a pregnancy still benefits from attention to her insulin sensitivity, her lipid profile, her blood pressure trajectory, and her body composition. Treating only the cycle features and waiting for her to come back for fertility is the old PCOS model. The new PMOS model treats the metabolism throughout.

Ovarian

The third word is the most familiar — it is the only word retained from the original name. Ovarian disturbance remains a defining clinical feature of PMOS, and most women still come to a specialist because of an ovulation-related problem: irregular cycles, infrequent periods, or difficulty conceiving.

What ovarian refers to in the new name is more precisely defined than under the old. Two features matter clinically.

The first is ovulatory dysfunction — periods that are infrequent, irregular, or absent, reflecting cycles in which the ovary either does not release an egg or does so inconsistently. This is the most common reason women seek evaluation, and it remains a core diagnostic criterion.

The second is the ovarian morphology — the ultrasound appearance of multiple small follicles arranged in a characteristic pattern. The old name described these as cysts. They are not cysts in the medical sense. They are immature follicles that have not progressed to ovulation, arrested at an earlier stage of development. The pattern reflects the underlying hormonal disturbance; it is not the disturbance itself. In the current diagnostic framework⁵, this feature is no longer used as a criterion in adolescents because immature follicles are common in adolescent ovaries even without PMOS.

The reason ovarian is the third word in the new name rather than the first is that it is downstream, not foundational. The ovary does what the hormonal environment tells it to do. Treating PMOS at the ovarian level alone — for example, by inducing ovulation pharmacologically — works for the immediate goal of conception but does not address the underlying polyendocrine and metabolic environment that produced the ovulatory disturbance to begin with.

Putting it Together

The three words form a clinical hierarchy that has practical consequences.

Polyendocrine is the most foundational. It names the multi-system interaction that produces the condition. Treatment must address this interaction, not any single axis in isolation. Treating only the ovary, or only the insulin axis, or only the androgens, will not work in the long run because the systems feed back into each other.

Metabolic is the most consequential for long-term health. It is the dimension that determines what happens to a woman with PMOS across the decades after her reproductive years. Treatment must address this dimension regardless of whether she is currently trying to conceive.

Ovarian is the most acute and the most fertility-relevant. It is the feature that brings most women to a specialist and the feature that resolves most quickly once treatment is working. Treatment of the ovarian features alone is a downstream intervention; it works in the short term but does not address the underlying condition.

A PMOS clinical conversation that takes all three dimensions seriously is a PMOS conversation done well. A conversation that addresses only one — usually, under the old PCOS framing, the ovarian — is the historical pattern the rename was designed to correct.

For the broader picture of how PMOS is recognised, diagnosed, and treated, see the pillar article Understanding PMOS.

About the Author

Dr Gautam V. Daftary is Director of Aksigen IVF and a senior consultant in reproductive medicine. He is a senior author on the 2026 review of PCOS / PMOS in the Indian context published inInsights in Reproductive Medicine.

This article is part of the Bharat Daftary Knowledge Centre, the patient-education programme of Aksigen IVF. It is intended for general information and does not replace consultation with a qualified clinician.

References

Teede HJ, Bahri Khomami M, Morman R, et al.Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process.The Lancet. Published online May 12, 2026. DOI: 10.1016/S0140-6736(26)00717-8.
Dapas M, Dunaif A. Deconstructing a syndrome: genomic insights into PCOS causal mechanisms and classification. Endocrine Reviews.2022;43(6):927–965. DOI: 10.1210/endrev/bnac001.
Wekker V, van Dammen L, Koning A, et al. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Human Reproduction Update. 2020;26(6):942–960. DOI: 10.1093/humupd/dmaa029.
Tay CT, Mousa A, Vyas A, Pattuwage L, Tehrani FR, Teede H. 2023 International Evidence-Based Polycystic Ovary Syndrome Guideline Update: Insights From a Systematic Review and Meta-Analysis on Elevated Clinical Cardiovascular Disease in Polycystic Ovary Syndrome. Journal of the American Heart Association.2024;13:e033572.
Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT, et al., on behalf of the International PCOS Network. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Human Reproduction. 2023;38(9):1655–1679.

Aksigen IVF•Bharat Daftary Knowledge Centre•What “Polyendocrine Metabolic Ovarian” Actually Means, v1.0•June 2026

What "Polyendocrine Metabolic Ovarian" Actually Means